FDA asks Teva Pharmaceutical for further study on Huntington drug

Your Health Matters

Israel-based Teva Pharmaceutical Industries said on Tuesday approval for a drug to treat chorea stemming from Huntington disease (HD) has been held up by U.S. regulators seeking further blood study. Teva, the world’s largest generic drugmaker, said it received a letter from the Food and Drug Administration for SD-809 for the treatment of chorea – abnormal, involuntary writhing movements that occur in 90 percent of HD patients at some point in the course of their illness. “The FDA has asked Teva to examine blood levels of certain metabolites.
Go to Source

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave